Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669890 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL28866775 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL497515 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL3369452 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL4669921 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL3780597 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL2897972 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL1221172 | 1.00 | ACE (0.60) | ACELMNAABCB11MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7264173 | 0.99 | ACE (0.59) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL11041388 | 0.99 | ACE (0.59) | ACELMNAABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284957-B1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2008-05-07 | — | — | EP | claimed |
| US-7071349-B2 | Purification method of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine | KANAKA CORPORATION (JP) | 2006-07-04 | — | — | US | claimed |
| EP-1284957-A4 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2004-12-29 | — | — | EP | claimed |
| US-20030162991-A1 | Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1284957-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2003-02-26 | — | — | EP | claimed |
| WO-2002074728-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2002-09-26 | — | — | WO | claimed |
| EP-1284957-B1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-7071349-B2 | Purification method of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine | KANAKA CORPORATION (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-1284957-A4 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20030162991-A1 | Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1284957-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2003-02-26 | — | — | EP | disclosed |
| WO-2002074728-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2002-09-26 | — | — | WO | disclosed |
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
| EP-0338508-A2 | Esters from amino-acids, their preparation process, drugs containing same and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162991-A1 | Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine | ANPEP, NPEPPS, ADH1A | ACE 308/4885LMNA 268/4885ABCB11 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.